MaxCyte Inc (LON:MXCT)‘s stock had its “buy” rating restated by analysts at Panmure Gordon in a research note issued on Tuesday. They currently have a GBX 170 ($2.22) price target on the stock. Panmure Gordon’s price target would suggest a potential upside of 101.18% from the stock’s previous close.

MaxCyte (LON:MXCT) opened at 83.00 on Tuesday. MaxCyte has a 1-year low of GBX 75.00 and a 1-year high of GBX 86.38. The stock’s market capitalization is GBX 36.08 million. The stock’s 50 day moving average price is GBX 84.50 and its 200 day moving average price is GBX 82.05.

About MaxCyte

MaxCyte, Inc focuses on cell-based medicines. The Company’s cell modification technology, Flow electroporation, is used for discovery, development and manufacture of small molecule, biologic and cell-based therapeutics. The Company’s products include instruments, processing assemblies and insourcing services.

Receive News & Ratings for MaxCyte Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.